19 June 2013
Keywords: kosan, opens, ph, ii, study, alvespimycin, usa-based
Article | 28 January 2008
USA-based biotechnology firm Kosan Biosciences has initiated a Phase II trial of alvespimycin, its second-generation Hsp90 inhibitor, in
patients with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 January 2008
18 June 2013
© 2013 thepharmaletter.com